Waring E M
Department of Psychiatry, Queen's University, Ontario.
Can J Psychiatry. 1995 Sep;40(7 Suppl 2):S33-7. doi: 10.1177/070674379504007s02.
To examine research and clinical interest in the first episode of schizophrenia. Pathobiological features have been shown to be a consequence of the disorder rather than the effects of chronicity, drug treatment or institutionalization. There is increasing evidence that ventricular enlargement is a robust finding and hypofrontality on PET and SPECT is associated more with symptomatology than with neuroleptic treatment.
Neuroleptic threshold studies suggest that lower daily dosages and onset of medication may be the most important response prediction parameters.
The role of novel antipsychotics in the treatment of first-onset schizophrenia merits investigation for lower rates of extrapyramidal syndromes and tardive dyskinesia. To reduce relapse rates, psychiatrists need to introduce practice standards employing those biopsychological features in the management of first-episode schizophrenia.
研究对精神分裂症首发期的研究及临床关注情况。病理生物学特征已被证明是该疾病的结果,而非慢性病程、药物治疗或住院治疗的影响。越来越多的证据表明,脑室扩大是一个确凿的发现,正电子发射断层扫描(PET)和单光子发射计算机断层扫描(SPECT)显示的额叶功能低下更多地与症状学相关,而非与抗精神病药物治疗相关。
抗精神病药物阈值研究表明,每日较低剂量及药物起始使用可能是最重要的反应预测参数。
新型抗精神病药物在首发精神分裂症治疗中的作用值得研究,因其锥体外系综合征和迟发性运动障碍的发生率较低。为降低复发率,精神科医生在首发精神分裂症的管理中需要引入采用那些生物心理特征的实践标准。